Understanding Your Biopsy and Dysplasia Grade
At a Glance
An oral leukoplakia biopsy checks for dysplasia, or abnormal cells in the mouth’s lining. The grade helps estimate the chance of future cancer, but a no-dysplasia result does not remove all risk because a small sample can miss a worse area or cells can change later.
While your doctor can see the color and shape of a white patch, only a pathologist can see what is happening at the cellular level. When a piece of tissue is removed during a biopsy, it is examined for oral epithelial dysplasia (OED)—a term for abnormal changes in the size, shape, and organization of the cells that line your mouth [1][2].
Dysplasia is not cancer, but it is a “pre-cancerous” signal that the cells are no longer growing normally [3]. Understanding your pathology report is a key step in managing your long-term oral health.
The Grading Spectrum
Pathologists use a grading system to describe how “worrisome” the abnormal cells look under the microscope. There are two main ways this is reported:
- The Three-Tier System: This is the most common method, grading dysplasia as mild, moderate, or severe [4].
- The Binary System: Some modern reports simplify this into two categories: low-grade and high-grade [6]. (Note: The binary system does not map perfectly to the three-tier system; the pathologist’s integrated interpretation matters most).
Why Grade Matters: Risk of Transformation
The grade of dysplasia is one of the strongest predictors of whether a patch might eventually turn into cancer. In a large cohort study, the estimated 5-year risk of cancer progression was approximately [7]:
- Mild Dysplasia: 11.9%
- Moderate Dysplasia: 8.7% (Note: This slightly lower number may reflect how these cases were sampled or managed clinically in this specific study) [7].
- Severe Dysplasia: 32.2%
These percentages are estimates from a specific population, not fixed biological probabilities for your exact lesion. Grade is not the sole determinant of your risk.
The “No Dysplasia” Caveat
It is a huge relief when a biopsy report says “no dysplasia”. However, this result does not mean the risk is zero [7].
In one major clinical cohort, roughly 39.6% of the eventual cancers actually came from patches where the initial biopsy sample had shown no dysplasia [7]. This happens for two main reasons:
- Sampling Error: An incisional biopsy (often taken with a scalpel or punch) only takes a small sample of the patch [8]. Because leukoplakia is heterogeneous, the sample might have missed a more aggressive area just a few millimeters away [8][9].
- Future Changes: The cells may be healthy today but could undergo genetic changes and become dysplastic months or years later [10].
For these reasons, even a “clean” biopsy requires continued monitoring by your doctor [11].
Biopsy vs. Full Removal
Because a small biopsy can sometimes underestimate the severity of a lesion, there is often a discrepancy between the biopsy result and what is found if the entire patch is later surgically removed [12].
Studies have shown that in cases where there is a disagreement between the two, the biopsy assigned a lower grade about 41% of the time [12]. This is why your doctor may still recommend removing a “mild” patch if it is in a high-risk location like the tongue or if it looks suspicious to their trained eye [9][13].
Reading Your Report
When you look at your pathology report, keep an eye out for these terms:
- Hyperkeratosis/Parakeratosis: Increased thickness of the keratin layer, or retained nuclei. While these often accompany a reactive “callus”, they are microscopic descriptions and do not by themselves exclude dysplasia [11].
- Atypia: A general term for cells that look slightly unusual but don’t quite meet the full criteria for dysplasia [1].
- Differentiated Dysplasia: A specific type of abnormal cell growth that can be harder to spot but carries its own risk of progression [14].
If your report mentions any of these, or if you are unsure of the grade, it is perfectly appropriate to ask for a review by an oral and maxillofacial pathologist, who specializes specifically in diseases of the mouth [12].
What to Expect From Your Biopsy
If you are getting a biopsy, expect a procedure involving local anesthetic. You may experience some soreness and light bleeding, and you might receive stitches. Ask your clinician when the pathology results will be discussed, whether the sample is representative, and whom to contact if you develop bleeding or signs of infection.
Common questions in this guide
What does oral dysplasia mean on a leukoplakia biopsy?
What is the difference between mild, moderate, and severe dysplasia?
Can oral leukoplakia become cancer even if the biopsy shows no dysplasia?
Why might a doctor recommend removing a mild leukoplakia patch?
Should an oral and maxillofacial pathologist review my biopsy?
What should I expect after an oral leukoplakia biopsy?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Can you walk me through the specific architectural or cytological features the pathologist noted in my report?
- 2.Did the pathologist see any 'differentiated dysplasia,' and how does that affect my risk compared to 'classic' dysplasia?
- 3.Given the size and appearance of my patch, are you confident the biopsy sample came from the most concerning area?
- 4.If my result shows no dysplasia but the patch doesn't go away, how often should we repeat the biopsy?
- 5.Should my pathology slides be reviewed by an oral and maxillofacial pathologist for a second opinion on the grading?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Demystifying oral epithelial dysplasia: a histological guide.
Hankinson P, Mahmood H, Walsh H, et al.
Pathology 2024; (56(1)):11-23 doi:10.1016/j.pathol.2023.10.002.
PMID: 38030478 - 2
Cytokeratin 13 and 17 expressions in oral epithelial dysplasia: correlation with the 5th WHO architectural and cytological features.
Hirunwidchayarat W, Lam-Ubol A, Limsitthigool K, Udompatanakorn C
Odontology 2026; doi:10.1007/s10266-026-01513-1.
PMID: 42518059 - 3
Diagnosis of differentiated dysplasia as a variant of oral epithelial dysplasia.
Becker AS, Holm M, Liese J, et al.
Oral diseases 2024; (30(7)):4185-4194 doi:10.1111/odi.14846.
PMID: 38191851 - 4
Oral epithelial dysplasia: Causes, quantification, prognosis, and management challenges.
Tilakaratne WM, Jayasooriya PR, Jayasuriya NS, De Silva RK
Periodontology 2000 2019; (80(1)):126-147 doi:10.1111/prd.12259.
PMID: 31090138 - 5
A head-to-head comparison of four grading systems for oral epithelial dysplasia.
Hankinson P, Clark M, Walsh H, Khurram SA
Histopathology 2025; (86(6)):933-941 doi:10.1111/his.15400.
PMID: 39688116 - 6
Ki67, CD105, and α-SMA expressions better relate the binary oral epithelial dysplasia grading system of World Health Organization.
Gadbail AR, Chaudhary MS, Sarode SC, et al.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2017; (46(10)):921-927 doi:10.1111/jop.12612.
PMID: 28672080 - 7
Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.
Chaturvedi AK, Udaltsova N, Engels EA, et al.
Journal of the National Cancer Institute 2020; (112(10)):1047-1054 doi:10.1093/jnci/djz238.
PMID: 31860085 - 8
Predicting Progression of Low-Grade Oral Dysplasia Using Brushing-Based DNA Ploidy and Chromatin Organization Analysis.
Datta M, Laronde DM, Rosin MP, et al.
Cancer prevention research (Philadelphia, Pa.) 2021; (14(12)):1111-1118 doi:10.1158/1940-6207.CAPR-21-0134.
PMID: 34376461 - 9
Diagnostic utility of microsurgical carbon dioxide laser excision of oral potentially malignant lesions vs incisional biopsy: a retrospective histopathological review.
Vu J, Coleman HG, Palme CE, et al.
Oral surgery, oral medicine, oral pathology and oral radiology 2019; (127(6)):516-525 doi:10.1016/j.oooo.2018.12.010.
PMID: 30948343 - 10
Malignant Transformation and Long-Term Outcome of Oral and Laryngeal Leukoplakia.
Bukovszky B, Fodor J, Tóth E, et al.
Journal of clinical medicine 2023; (12(13)) doi:10.3390/jcm12134255.
PMID: 37445290 - 11
Malignant Transformation Rate of Non-reactive Oral Hyperkeratoses Suggests an Early Dysplastic Phenotype.
Stojanov IJ, Woo SB
Head and neck pathology 2022; (16(2)):366-374 doi:10.1007/s12105-021-01363-z.
PMID: 34255278 - 12
Diagnostic discrepancies in the surgical management of oral epithelial dysplasia - an analysis of concordance between incisional biopsy and definitive resection specimens.
Maloney B, Jung MS, Byrne J, et al.
Oral surgery, oral medicine, oral pathology and oral radiology 2026; (142(3)):362-374 doi:10.1016/j.oooo.2026.03.001.
PMID: 42020233 - 13
Clinicopathologic factors associated with malignant transformation of oral leukoplakias: a retrospective cohort study.
Jäwert F, Pettersson H, Jagefeldt E, et al.
International journal of oral and maxillofacial surgery 2021; (50(11)):1422-1428 doi:10.1016/j.ijom.2021.01.012.
PMID: 33674140 - 14
The role of differentiated dysplasia in the prediction of malignant transformation of oral leukoplakia.
Wils LJ, Poell JB, Peferoen LAN, et al.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2023; (52(10)):930-938 doi:10.1111/jop.13483.
PMID: 37749621
This page explains oral leukoplakia biopsy results and dysplasia grades for informational purposes only and does not constitute medical advice. Ask your clinician or an oral and maxillofacial pathologist to interpret your report and plan follow-up.
Get notified when new evidence is published on oral mucosa leukoplakia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.